Teva Pharmaceutical Industries Ltd.'s latest update on fremanezumab in cluster headaches will lessen the calcitonin gene-related peptide (CGRP) inhibitor's potential market by a few hundred thousand patients, but the biologic's main opportunity lies in the much larger migraine headache market.
Teva said on June 15 that it will discontinue a Phase III clinical trial testing fremanezumab in the prevention of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
